H.C. Wainwright raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $12 from $11 and keeps a Buy rating on the shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results